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The potential for mitochondrial (mt) DNA mutation accu-
mulation during antiretroviral therapy (ART), and prefer-
ential accumulation in patients with lipoatrophy compared
with control participants, remains controversial. We se-
quenced the entire mitochondrial genome, both before ART
and after ART exposure, in 29 human immunodeficiency
virus (HIV)–infected Swiss HIV Cohort Study participants
initiating a first-line thymidine analogue–containing ART
regimen. No accumulation of mtDNAmutations or deletions
was detected in 13 participants who developed lipoatrophy
or in 16 control participants after significant and comparable
ART exposure (median duration, 3.3 and 3.7 years, re-
spectively). In HIV-infected persons, the development of
lipoatrophy is unlikely to be associated with accumulation of
mtDNA mutations detectable in peripheral blood.
Lipoatrophy is an important and poorly reversible complication
associated with human immunodeficiency virus (HIV) infection
and antiretroviral therapy (ART), particularly the thymidine-
analogue nucleoside reverse-transcriptase inhibitors, stavudine
and zidovudine. The pathogenesis of lipoatrophy is in-
completely understood. A widely implicated mechanism is mi-
tochondrial dysfunction, which is associated with HIV infection
and thymidine-analogue treatment [1].
Several studies now suggest a genetic predisposition to
lipoatrophy, but results have not been uniform regarding, for
example, an association with certain mitochondrial DNA
(mtDNA) haplogroups [2–4]. A related question is the po-
tential for mtDNA genomic damage, possibly induced by
thymidine analogues, to contribute to lipoatrophy [5, 6]. The
accumulation of mtDNA point mutations has been experi-
mentally linked to premature aging [7], and advancing age is
an unexplained risk factor for lipoatrophy in HIV-infected
persons [8]. Martin et al [5] recorded the accumulation
during ART of multiple mutations in mtDNA extracted from
the peripheral blood. The mtDNA mutations were preferen-
tially seen in patients who developed lipoatrophy compared
with control participants without lipoatrophy. However, the
lipoatrophy case patients had more intensive ART exposure
than the control patients; therefore, it remained possible that
lipoatrophy or mtDNA mutations might have developed with
prolonged ART exposure in the participants classified as
controls [5]. In a second study with longitudinal mtDNA
samples, McComsey et al [6] observed no accumulation of
mtDNA mutations in peripheral blood samples, but the me-
dian duration of follow-up was only 13 months.
This study was therefore conducted to reassess the value of
mitochondrial genome sequencing in HIV-infected participants
with and without lipoatrophy, and with significant and com-
parable ART exposure. We assessed a potential correlation be-
tween the development of lipoatrophy and the accumulation of
mtDNA mutations in peripheral blood.
METHODS
Study participants were enrolled in the Swiss HIV Cohort Study
(SHCS; http://www.shcs.ch), which involves a standardized
clinical evaluation of fat loss and fat accumulation every
6 months. Participants gave written, informed consent for ge-
netic testing. The SHCS Genetics Project was approved by the
ethics committees of participating centers. Participants were
male and self-identified as white, to minimize the influence
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of sex and of population structure on mtDNA sequences.
Each participant started a first-line zidovudine- or stavudine-
containing combination ART regimen after 1 April 1998, had
a cell sample stored prior to ART initiation, and had no fat loss
recorded prior to ART. Case patients developed significant fat
loss (patient/physician agreement; >2 body sites), consistently
recorded at >4 subsequent, biannual SHCS visits, without
reversion to no fat loss. To avoid excluding participants who
rapidly developed lipoatrophy, we required no minimum du-
ration of ART. Controls had no fat loss for >3 years after ART
initiation.
We permitted modifications of ART components other than
zidovudine or stavudine. We excluded participants with ART
interruption for >30 days as well as those with initial immune
reconstitution followed by a CD4 cell decline to ,200 cells/lL,
to exclude significant complications (eg, tuberculosis or lym-
phoma) as confounding factors for fat loss. To exclude ART
nonadherence or active viral replication as a confounder for the
presence or absence of lipoatrophy, all participants had HIV
RNA counts of ,400 copies/mL starting >1 year after ART
initiation.
The treating HIV physician confirmed in writing the presence
or absence of lipoatrophy and interviewed each participant re-
garding his ancestry. We assessed the value of clinical lipoa-
trophy classification by quantitative assessment of total and
regional fat mass by dual-energy x-ray absorptiometry (DEXA;
Hologic QDR-4500W) in a subset of study participants. DEXA
provided quantitative assessments of total body mass, peripheral
(sum of arm and leg fat) and total fat mass, and the ratio be-
tween peripheral and total fat mass to adjust for differences in
body weight [9].
Sequencing and Mutational Screening of mtDNA
We extracted mtDNA from frozen leukocyte pellets. We se-
quenced the entire genomic (16569 bp) mtDNA at 2 time
points: prior to any ART exposure, and after lipoatrophy di-
agnosis (cases) or after >3 years of ART (controls). Polymerase
chain reaction (PCR) amplification and direct forward and re-
verse sequencing was performed by Macrogen, using BigDye
Terminator sequencing chemistry on a 3730XL DNA Sequencer
(Applied Biosystems). Primers and PCR conditions were as
published elsewhere [10]. ABI PRISM SeqScape software (ver-
sion 2.6; Applied Biosystems) was used to analyze the electro-
pherogram files. All sequences were analyzed without knowledge
of sample classification as case or control. We performed quality
checks of mtDNA sequences as described in the supplementary
material. We aligned mtDNA sequences and compared them
with the revised Cambridge reference sequence (available at
http://jid.oxfordjournals.org/) using SeqScape and further
manual check. We classified variant positions relative to this
reference sequence either as phylogenetically informative (useful
to assign a particular sequence to a mtDNA haplogroup) or
uninformative [11]. Among the latter class, we distinguished
mutations occurring in the mtDNA coding region, which have
the potential to be nonsynonymous, from those occurring in the
noncoding control region. We used 3 large databases to identify
known sequence variants in humans: PhyloTree (http://
www.phylotree.org), MITOMAP (http://www.mitomap.org),
and mtDB (http://www.genpat.uu.se/mtDB/). We made classi-
fications into haplogroups using the phylogenetic tree of global
human mtDNA variation by van Oven and Kayser [12], avail-
able at PhyloTree.
RESULTS
We included 13 case patients with lipoatrophy and 16 control
patients without lipoatrophy, whose characteristics are shown in
Table 1. Lipoatrophy was first noted in case patients after
a median ART duration of 2 years (interquartile range [IQR],
1.5–3.3 years). Of the 6 case patients and 4 control patients that
underwent DEXA, the cases had higher body weight, total
mass, and total fat, and slightly more peripheral fat than the
controls, but despite this, their peripheral to total fat ratio was
decreased, consistent with lipoatrophy [9]. However, these dif-
ferences were not statistically significant in this small study
population (Table 1).
The entire mtDNA was sequenced from samples taken before
ART and after a median ART duration of 3.3 years in cases and
3.7 years in controls. Comparison of each participant’s mtDNA
sequences before and during ART revealed no point mutations,
no insertions or deletions, and no evidence of point hetero-
plasmy in any samples (Supplementary Table 1).
Participants belonged to the main mtDNA haplogroups H, U,
K, J, and L (13, 7, 2, 6, and 1 participant, respectively). Thus, H
and U were most frequent haplogroups, followed by J and K,
findings that are consistent with the European origin of the
participants (see Supplementary Results), whereas 1 participant
carried an L haplogroup (L0a2a2a). By pooling certain hap-
logroups (ie, U and K; J and L), a formal test of homogeneity
showed that this simplified haplotype distribution did not de-
viate from 3 previously published western European regional
samples (P 5 .55, P 5 .40, and P 5 .14, respectively; see Sup-
plementary Results). A slight excess of haplogroup J (21%) was
observed in the study population, compared with 10%, 9%, and
6%, respectively, in the regional European samples.
Case participants who belonged to mtDNA haplogroups H,
U, K, J, and L numbered 6, 4, 1, 2, and 0, respectively, and
control participants numbered 7, 3, 1, 4, and 1. No formal
comparison of the frequency distribution of haplogroups be-
tween cases and controls was feasible because of limited sample
size. Single haplogroup frequency comparison indicated that the
frequency of haplogroup H did not differ between cases and
controls (P. .05), and haplogroup J was more frequent among
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Table 1. Clinical Characteristics of 13 Case Patients With Lipoatrophy and 16 Control Patients Without Lipoatrophy Who Had Previously Initiated a First-line thymidine
analogue–containing Antiretroviral Therapy Regimen
Lipoatrophy cases (n5 13) Controls without lipoatrophy (n 5 16) P1
Age at pre-ART mtDNA sample, median (IQR), years 51.8 (46.4–62.8) 45.1 (39.4–55) .16
Age at ART initiation, median (IQR), years 53.2 (46.4–62.8) 45.2 (39.6–55.1) .12
CD4 cell count at ART initiation, median (IQR), cells/lL 206 (142–224) 178 (117–238) .90
HIV RNA at ART initiation, median (IQR), copies/mL 77,000 (32,000–93,000) 176,000 (97,000–218,000) .03
Body weight at ART initiation, median (IQR), kg 72 (67–78) 70 (64–74) .41
Body mass index at ART initiation, median (IQR), kg/m2 23 (21.7–26.1) 22.5 (21.8–25.2) .46
Initial ART regimen NRTI components: ZDV13TC (n 5 11),
d4T1DDI (n 5 1), d4T13TC (n 5 1);
Third agent: efavirenz (n 5 6), nelfinavir (n 5 4),
lopinavir/ritonavir (n 5 2), indinavir (n 5 1)
NRTI components: ZDV13TC (n 5 12),
ZDV13TC1ABC (n 5 1), d4T1DDI (n 5 2),
d4T13TC (n 5 1);
Third agent: efavirenz (n 5 5), nelfinavir (n 5 4),
lopinavir/ritonavir (n 5 4), indinavir (n52),
saquinavir/ritonavir (n 5 1)
.81
.50
Age at during-ART mtDNA sample, median (IQR), years 56 (49.8–66.1) 48.8 (43.6–58.3) .18
Cumulative ART exposure at during-ART mtDNA
sample, median (IQR), years
3.3 (2.5–4.1) 3.7 (3.4–3.8) .16
Body site(s) of fat loss Face (n 5 9), arms (n 5 12), legs (n 5 11),
buttocks (n5 3)
No fat loss
Fat accumulation n5 9 n5 5
Hyperlactatemia, peak level, symptoms/acidosis n5 1, 2.6 mmol/L, asymptomatic n 5 1, 5.9 mmol/L, asymptomatic
Peripheral neuropathy n5 2 (attributed to vitamin B12 deficiency in 1
participant)
n5 1 (attributed to diabetic neuropathy)
Pancreatitis None None
DEXA, number of participants 6 4
d Age at DEXA, median (IQR), years 59.3 (53.7–66.9) 51.4 (44.8–59.9) .41
d Total mass, median (IQR), kg 72 (60.8–72.3) 67.4 (63.4–68.3) .21
d Total fat, median (IQR), kg 15.3 (11.6–18.9) 10.3 (9.5–11.9) .41
d Peripheral fat, median (IQR), kg 4.9 (4.3–6.7) 4.6 (4–5.2) .54
d Peripheral/total fat ratio, mean % 37.9 41.4 .54
NOTE. Abbreviations: ART, antiretroviral therapy; mtDNA, mitochondrial DNA; IQR, interquartile range; DEXA, dual-energy x-ray absorptiometry
1 P values of tests for equality of distribution in lipoatrophy cases versus controls without lipoatrophy. All comparisons performed applying the Mann-Whitney U test except for initial ART regimens, which were compared
with the v2 homogeneity test (collapsed categories: zidovudine vs stavudine, and efavirenz vs nelfinavir vs other).
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controls, whereas haplogroup U was slightly more common
among cases (both P . .05).
We also compared mtDNA sequences with the revised
Cambridge reference sequence. As expected, numerous variant
mtDNA positions or small insertions or deletions were in-
dentified. Among 90 phylogenetically uninformative variant
positions (43 in the coding region, 47 in the noncoding control
region), 86 are known to be polymorphic in the human pop-
ulation, thus providing no signal of a possible association with
lipoatrophy (see Supplementary Results). Among the 4 variants
not previously recorded as polymorphic, only 1 (a single tran-
sition at mtDNA position 7962 in a lipoatrophy case bearing
haplogroup H) was nonsynonymous.
DISCUSSION
Using whole mitochondrial genome amplification and direct
sequencing, we observed no accumulation of mtDNAmutations
or deletions in a comprehensive mtDNA sequence analysis of an
HIV-infected study population that included 13 case partic-
ipants with lipoatrophy and 16 control participants without
lipoatrophy. In both cases and controls, mtDNA was sequenced
twice: first while participants were ART-naı¨ve and again after
substantial (median, >3.3 years) and comparably extensive ex-
posure to thymidine analogue–containing ART. This finding
argues against the accumulation of mtDNA mutations as a ma-
jor driver behind the development of lipoatrophy. In addition,
no signal was detected when comparing mtDNA haplogroups in
cases and controls, or when comparing mtDNA sequences with
the revised Cambridge reference mtDNA sequence.
The accumulation of multiple mtDNAmutations over time is
the central tenet of the mitochondrial hypothesis of aging that
has been experimentally validated in the mtDNA ‘‘mutator
mouse’’ model [7]. However, the link between mtDNA damage
and metabolic complications in HIV-infected individuals re-
mains circumstantial. Previously, 2 groups have assessed the
mitochondrial genome for longitudinal mtDNA changes during
ART. In the study by Martin et al [5], mtDNA mutations ac-
cumulated during follow-up in 1 of 11 patients without lipoa-
trophy and in 4 of 5 patients with lipoatrophy. However,
patients without lipoatrophy had a shorter mean ART duration
(1.9 years) than the that of the lipoatrophy case patients (3.5
years). McComsey et al [6] recorded the longitudinal reversion of
heteroplasmic mtDNA sequence variants to homoplasmic ones
in no participant with lipoatrophy and 2 participants without
lipoatrophy. However, this occurred in the hypervariable
mtDNA control region, themedian duration of follow-up in this
study was only 13 months, and the authors expressed concern
that the method used to detect any mtDNA mutations (tem-
poral temperature gradient gel electrophoresis [TTGE] of the
PCR products) may have been insufficiently sensitive.
Moreover, in both studies [5, 6], all recorded mtDNA mu-
tations were heteroplasmic. He et al [13] recently reported the
use of massively parallel sequencing-by-synthesis approaches to
statistically quantify heteroplasmy. A high level of heteroplasmy
was seen in normal participants, with variable frequencies
among tissues. Thus, mtDNA heteroplasmy may not represent
an important end point in lipoatrophy genetic studies, unless
a significant heteroplasmy increase were detected preferentially
after ART exposure, and in lipoatrophy participants compared
with patients without lipoatrophy.
Our study is limited by sample size to detect mtDNA hap-
logroup associations and by clinical diagnosis of lipoatrophy.
However, we included participants only if significant lipoa-
trophy was consistently present during follow-up, case or con-
trol status was confirmed in writing by the treating HIV
physician, and by DEXA assessment of the study criteria in
a subset of participants. Another limitation of studies of the
mtDNA genome in HIV-infected persons is the source of
mtDNA, which is extracted from the most accessible tissue (ie,
peripheral blood). As with mtDNA depletion, if and to what
extent mtDNA sequences in blood correlate with mtDNA se-
quences in affected tissue (ie, subcutaneous fat) is unclear [14].
The mitochondrial toxicity hypothesis of lipoatrophy [1] has
evolved from a hypothesis centered on polymerase-c to a more
complex picture including the differential effects of ART in
different tissue compartments. For example, recently, Payne et al
[15] identified mtDNA variants in muscle biopsies, but point
mutations were only found in cytochrome c oxidase–deficient
fibers (ie, cells with mitochondrial dysfunction).
In conclusion, our findings, in conjunction with the reports
by Martin et al [5] and McComsey et al [6], suggest that lip-
oatrophy genetic studies based on peripheral blood mtDNA
specimens may not permit the detection of possible mtDNA
changes in particular tissue types or cell populations. Sub-
cutaneous fat biopsy samples seem best suited to evaluate
a possible role for mtDNA genomic variation in the patho-
genesis of lipoatrophy. Patient acceptance limits the feasibility
of fat biopsies, particularly in the setting of a longitudinal study,
and the paucity or lack of fat tissue in lipoatrophy patients may
be a problem. In contrast, peripheral blood samples are suffi-
cient to identify potentially lipoatrophy-predisposing single
nucleotide polymorphisms in nuclear encoded genes, including
TNF -238G . A, APOC3, hemochromatosis gene variants,
FAS, AR Beta-2, HLA-B*4001, and potentially lipoatrophy-
predisposing mtDNA haplogroups [2–4].
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